Ruti Aga's Six-Year Ban: How a Forged Prescription Turned a Two-Year Case into Six

The Athletics Integrity Unit released its statement on a Thursday afternoon. I did what I always do first: I opened the results sheet, then read the statement. There was no result on the sheet. A half marathon in China in March, won, and then blank space. No finishing time. No five-kilometre split. Not a word about who else was in the field. The one thing in the file that could actually be checked was not a mark — it was a drug name. And the file got that wrong too. Methylprednisolone. Nearly every report called it a “prohibited steroid” and said WADA classes it as performance-enhancing. That is imprecise and it is misleading. Methylprednisolone is a glucocorticoid, class S9 on the WADA Prohibited List, and S9 is prohibited in-competition only — by injection, oral or rectal route. It is not an S1 anabolic steroid. This is not pedantry. The whole case hung on it. For an S9 substance, a defence existed: route, timing, medical necessity. The forged prescription closed that door, and then four additional years walked in behind it. Now the context. Ruti Aga, 32, Ethiopia, marathon. Winner of the 2026 Tokyo Marathon. Three second-place finishes at World Marathon Majors. Her personal best sits in my notes at 2:18:34, Berlin 2026, where she finished second. That figure comes from recall, not from the source text, so treat it as pending verification. I do not trust a trend until I can reconcile it to the ledger, and here the ledger has holes. What the ledger does hold: a 2:18–2:20 class marathoner whose career peaked in 2026–2026, with no reported PB improvement after that. That is a plateau, not a decline — but for a 32-year-old standing on a plateau, a six-year ban is indistinguishable from a decline. The depth of Ethiopian women's marathoning is such that a 2:18 performer is not automatically selectable. Put that in numbers: the door to a national team opens at a time faster than 2:18, and the capacity of that team is not determined by the absence of one athlete. A single removal is invisible at national-team level. Then the stage where this case was built — China's Label half-marathon circuit. For East African marathoners this is the income tier between Majors: high appearance fees, few races, low risk. Winning a half marathon in China in March is part of that model. It is also now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races. Here is the part that makes this more than a positive test. The glucocorticoid rule is simple, and its simplicity is what makes it hard. S9 substances are prohibited in-competition, not out of it. A methylprednisolone injection into a knee, administered days before a race, is not in itself a violation. It becomes one when residues are present in an in-competition sample. The case therefore rested on route and timing, not on “steroid use.” One technical point that barely surfaced in the reporting: the in-competition testing window for a road race opens at 23:59 the day before the race. An injection given three or four days out can still be caught, if residues remain. The athlete who reasons “I did the treatment out of competition” is caught by that window's arithmetic. The defence available here was exactly that — clean medical records, a disclosed route, a timing calculation. That defence never happened. I traced the prescription, and it broke in three places. First, the clinic. The clinic named on the prescription did not exist. Second, the doctor. The person who issued it was not a registered medical practitioner — he was a family member. Third, the pad. He claimed to have used “an old prescription pad from a former workplace,” and the institution named on that pad stated plainly that it had no connection to him. Three independent verifications, three failures. This is not a filing error. It is the signature of an athlete operating without a credentialed team physician. No TUE infrastructure — no application, no exemption, no route-specific washout observance. What she had was the cheapest, most available tool for masking pain, and the ability to manufacture paper. Now the arithmetic of the sanction. Six years, from 10 September. Read against the AIU statement, the arithmetic is clean: two years for the presence violation, four for tampering. Two plus four, six. Four years is the Code's standard tampering sanction, so that block is unremarkable. The two-year block tells us the panel declined the no-significant-fault mitigation that would have cut the presence sanction. There is a paradox here worth stating. A forged document is itself circumstantial evidence of concealment intent. It still did not aggravate the presence sanction — it added a separate one. The panel kept two things apart: the presence of the substance, and the attempt to hide that presence. The athlete traded two years for six, over a drug with no proven endurance benefit. Backdating to 10 September is procedural benefit, not a discount. Provisional suspension time counts against the ban. The athlete gains nothing in real terms; a date on paper slides forward. The statement gives the date twice — provisional suspension from 10 September, ban from 10 September. Three scenarios existed, and all three are on the ledger. The worst, which materialised: six years from 10 September, exposure on the March result and prize money, and the possibility of a national-level referral on document forgery, which sits outside AIU jurisdiction. The middle case, which a competent defence would have reached: with genuine medical records and a demonstrated route-and-timing explanation, the presence charge could have been argued at the no-fault end, and no tampering charge would have existed at all. The best case, which did not happen: a TUE-consistent treatment plan and correct washout timing, and no case whatsoever. The career cost. Six years at 32 means returning at roughly 38. Inside Ethiopian women's marathon depth, a 38-year-old with a doping record is effectively unselectable. The 2028 Olympic cycle is gone entirely. Under the stopwatch, every salary line becomes a performance claim — and here the salary line is the appearance fee that will no longer arrive. What survives is the 2026 Tokyo title and three Major runner-up finishes. The violation is anchored to a March race in a later year. Absent a finding of earlier use, results before that date are not automatically annulled. That is solid, and it is what I can enter in the ledger. The ledger also has a gap, and the gap needs naming. The source does not state the disqualification scope. Whether the March result and its prize money were voided is not written down. Standard AIU practice is automatic disqualification of the competition where the sample was collected, so the probability is high that both the result and the money are gone. But “the probability is high” and “it is written” are different things, and I will not smooth the difference away. A second gap: no statement from the Ethiopian federation appears in the source. Only the AIU is quoted. That absence is data too — it tells you no public national position has formed around this case. Now the part I find most interesting, and the part least likely to be written. The six-year ban is being read as evidence of AIU rigour. I read the ledger the other way. A substance with no proven endurance benefit produced six years — and it did so in a category where the sanction rests on paper, not on a blood sample. That is not a defence of the athlete; the forged prescription is her own work. But it tells you where enforcement is cheapest to run. Paper is cheap to check. Biological passport work is long and expensive. One prescription, one clinic, one registration — three checks in three phone calls. The model is clean; the incentive underneath it is what I interrogate. When the easiest investigative path is a document, the shape of enforcement becomes documentary — and the East African road-racing clusters whose medical support is informal are the first to fall into that shape. One more thing belongs on the record, though it is not in the source and is visible only in the case's architecture. The four-year tampering sanction came from an interview — from things said under questioning, not from a document alone. Language and interpretation conditions in AIU interviews have been a recurring point of contention for East African athletes. I have no evidence that interpretation was an issue in this interview, so I am not writing it as an allegation — only as a place where a question should be asked. And the warning I give myself. “Won a half marathon in China” tells you nothing about form. Do not turn it into evidence of form. There is no mark, no split, no field. Winning in March tells you she was fit enough to race and that the race was Label-tier, which is why in-competition testing existed. Nothing more. Filling in what is missing is record inflation, and it is the same error as reading a season's best as a failure. A small calculation from the coverage economy. The 2026 Tokyo win earned a fraction of the column inches this six-year ban is now earning. That is not a complaint; it is structure. A sanction is cheap to cover — a date, a number, a statement. Performance is expensive — splits, conditions, field strength, biomechanics. So the sanction prints first, and the performance prints later, if at all. And one column I deliberately keep non-quantitative, because the sheet cannot see it. The knee. Chronic knee pathology is not an accident for a marathoner; it is a known failure mode of high-volume training. The pressure to mask pain comes from the appearance-fee economy. A glucocorticoid is the cheapest answer to that pressure. And the surrounding medical network is informal. The prescription is the end of that chain, not the start. The start is a system in which an injured runner has a family member instead of a credentialed doctor. That is not sympathy. It is causal analysis. Fabricating a document was the athlete's decision, and the price is six years. But if the question is how this does not happen again, the answer is not document verification — the answer is access to a team physician who can put that injection on paper correctly. One name is missing from the statement. Someone advised on, or accepted, that document. The AIU named only the family member. Whether an agent or management was investigated is not in the source. That absence belongs on the record too, because the sanction here landed on one person, and the system that made it possible is still in place. What to watch next. Three signals go on my calendar. First, publication of the reasoned decision — it will clarify the disqualification scope and the prize-money question from the March race. Second, the CAS appeal window, typically about 21 days from the reasoned decision. A documentary forgery finding is hard to overturn, so the appeal's value is low — but the window is open. Third, China's Label circuit. High appearance fees, deep East African fields and AIU testing now occupy the same races. Results at that tier will carry integrity risk going forward. And the price, which I always put last. Six years, 32 to 38. For a 2:18 marathoner, that is six years of absence after three Major podiums. It was paid over a glucocorticoid whose benefit is unproven and whose defence was available. The defence rested on one sheet of paper. The paper was not real. The question is not whether the sanction was right. The question is what option an injured runner with no credentialed doctor will have next time — and who pays for it.